person · Reporting owner
Dockendorff Charles J
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | Director | May 09, 2024 | May 13, 2024 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2025 | July 25, 2025 |
| Keysight Technologies, Inc.KEYS · Entity 3021 | Director | March 20, 2026 | March 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date May 09, 2024 · Filed May 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,901 |
Reported balance
After 2024-05-09 transaction · row 1
1 source rowRow 1 · 2024-05-09 · Grant · Acquired 2,901 · Balance 2,901 F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse's Trust | 42,622 |
Reported balance
Holding disclosure · report date 2024-05-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 42,622 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 17,380 |
Reported balance
Holding disclosure · report date 2024-05-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 17,380 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
HAEMONETICS CORP
Report date July 24, 2025 · Filed July 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,126 |
Reported balance
After 2025-07-24 transaction · row 1
1 source rowRow 1 · 2025-07-24 · Grant · Acquired 2,693 · Balance 7,126 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
| Common StockSEC Table I · non-derivative | IndirectSpouse?s Revocable Trust | 17,915 |
Reported balance
Holding disclosure · report date 2025-07-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 17,915 |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Keysight Technologies, Inc.
Report date March 20, 2026 · Filed March 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,213.418 |
Reported balance
After 2026-03-20 transaction · row 1
1 source rowRow 1 · 2026-03-20 · Grant · Acquired 870 · Balance 55,213.418 F1: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 6,626 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 15,370 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.24 · Expires 2027-05-15 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 5,396 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.81 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 6,523 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.36 · Expires 2030-03-05 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 7,322 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.03 · Expires 2031-03-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 5,055 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.28 · Expires 2032-03-10 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 5,293 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.49 · Expires 2033-03-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 4,210 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.32 · Expires 2034-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Disposition to issuer · Disposed 4,536 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F4: For Footnote (4), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F4: For Footnote (4), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2021 Filed Feb 5, 2021 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 12,180 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001127602-21-004193 · form4.xml · derivative · entry 4 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,180 shares Expires 2021-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F5 · derivative.exercise_date: Options vest 100% on the first anniversary of the date of grant. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 12,180 | $134.53 | $1,638,575.40 |
DisclosureSEC source: 0001127602-21-004193 · form4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,755 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.14 to $135.00, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 12,180 | $35.50 | $432,420.45 |
DisclosureSEC source: 0001127602-21-004193 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:23 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021979 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,755 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007399 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,099 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 21:58 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 2,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001601046-20-000025 · wf-form4_158500069609757.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,214.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:01 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,322 | $0.00 Strike: $47.36 | $0.00 |
DisclosureSEC source: 0001127602-20-009970 · form4.xml · derivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,322 Underlying: Common Stock · 7,322 shares Expires 2030-03-05 F3 · derivative.exercise_date: Options become exercisable on the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:01 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009970 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,129 F1 · shares: Represents restricted stock units which vest on the date of the 2021 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025265 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,340 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:53 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028960 · a4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,099 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 22, 2019 Filed Mar 25, 2019 22:40 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 2,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-013156 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,776.418 F1 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 20:26 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,523 | $0.00 Strike: $46.81 | $0.00 |
DisclosureSEC source: 0001127602-19-010804 · form4.xml · derivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,523 Underlying: Common Stock · 6,523 shares Expires 2029-03-07 F3 · derivative.exercise_date: Options become exercisable on the date of the 2020 Annual Meeting of Stockholders Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 20:26 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-010804 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,912 F1 · shares: Represents restricted stock units which vest on the date of the 2020 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024053 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,880 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009199 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,213 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 20:42 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 3,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-012775 · form4.xml · nonDerivative · entry 3 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,425.418 F3 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the Keysight Technologies, Inc. 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. The reporting person has elected to defer these shares of common stock and such shares are held in a deferral account pursuant to the Defered Compensation Plan for Non-Employee Directors. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 20:42 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 779.575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-012775 · form4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,528.418 F2 · kind: The reporting person has elected to defer the committee retainer, and such cash has been converted into shares of common stock. The shares vested immediately and are held in a deferral account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 20:42 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 1,948.938 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-012775 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,748.843 F1 · kind: The reporting person has elected to defer the Board retainer, and such cash has been converted into shares of common stock. The shares vest quarterly, with 1/4th of the shares vesting on 3/23/18, and the remaining shares vesting on 6/23, 9/23, and 12/23 and are held in a deferral account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:20 UTC | HOLOGIC INC HOLX · Entity 12463 | PurchaseCommon Stock | 13,000 | $38.80 | $504,400.00 |
DisclosureSEC source: 0001127602-18-011827 · form4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:20 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,551 | $0.00 Strike: $38.44 | $0.00 |
DisclosureSEC source: 0001127602-18-011827 · form4.xml · derivative · entry 3 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2028-03-14 F3 · derivative.exercise_date: Options become exercisable on the date of the 2019 Annual Meeting of Stockholders. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:20 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011827 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,776 F1 · shares: Represents restricted stock units which vest on the date of the 2019 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 22:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,329 | $39.27 | $169,999.83 |
DisclosureSEC source: 0001127602-17-024407 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,184 F1 · shares: Restricted Stock Unit grant which vests 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 20:35 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | PurchaseCommon Stock | 13,210 | $37.81 | $499,470.10 |
DisclosureSEC source: 0001127602-17-021313 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,799.905 F1 · price: Average weighted price is $37.81 with a range from $37.785 to 37.840 Read SEC document |
| May 15, 2017 Filed May 16, 2017 21:48 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,396 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001127602-17-018377 · form4.xml · derivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,396 Underlying: Common Stock · 5,396 shares Expires 2027-05-15 F3 · derivative.exercise_date: Options become exercisable on the date of the 2018 Annual Meeting of Stockholders. Read SEC document |
| May 15, 2017 Filed May 16, 2017 21:48 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-018377 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 F1 · shares: Represents restricted stock units (RSUs) which vest and convert into shares of common stock on the date of the 2018 Annual Meeting of Stockholders. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009502 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,104 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 19:40 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 4,720 | $39.02 | $184,174.40 |
DisclosureSEC source: 0001127602-17-012358 · form4.xml · nonDerivative · entry 3 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,589.905 F3 · kind: Common stock underlying restricted stock units ("RSUs") granted pursuant to the Keysight Technologies, Inc. 2014 Equity and Incentive Compensation Plan. The RSUs vested immediately. The reporting person has elected to defer these shares of common stock and such shares are held in a deferral account pursuant to the Defered Compensation Plan for Non-Employee Directors. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 19:40 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 655.652 | $39.02 | $25,583.54 |
DisclosureSEC source: 0001127602-17-012358 · form4.xml · nonDerivative · entry 2 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,869.905 F2 · kind: The reporting person has elected to defer the committee retainer, and such cash has been converted into shares of common stock. The shares vested immediately and are held in a deferral account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 19:40 UTC | Keysight Technologies, Inc. KEYS · Entity 3021 | GrantCommon Stock | 2,360.346 | $39.02 | $92,100.70 |
DisclosureSEC source: 0001127602-17-012358 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,214.253 F1 · kind: The reporting person has elected to defer the Board retainer, and such cash has been converted into shares of common stock. The shares vest quarterly, with 1/4th of the shares vesting on 3/17/17, and the remaining shares vesting on 6/17, 9/17, and 12/17 and are held in a deferral account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.